Business
AstraZeneca chief quits CSL board over $50 billion acquisition – Sydney Morning Herald
AstraZeneca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup.
AstraZeneca announced its planned acquisition of Alexion for $US39 billion ($50.4 billion) in the second week of December, with Mr Soriot telling his investors the deal would allows us to enhance our presence in immunology.
Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player.
CSL, which is producing doses of AstraZenecas COVID-19 vaccine in Australia, told investors last year that Mr Soriots appointment did not look…
-
Noosa News20 hours agoFatal Traffic Crash, South Bingera
-
General24 hours agoThousands join pro-Palestinian rallies in towns and cities across Australia amid ceasefire
-
General23 hours agoAustralia’s Diamonds defeat South Africa’s Proteas 65-42 in third netball Test
-
General22 hours agoBathurst 1000 quick hits: Chaz Mostert drinks beer with fans, Erebus owner protests, and drama on Mount Panorama